Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Antimicrob Agents Chemother
; 67(11): e0096923, 2023 11 15.
Article
em En
| MEDLINE
| ID: mdl-37843260
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ceftazidima
/
Antibacterianos
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article